256 related articles for article (PubMed ID: 10719543)
1. [New developments in the treatment of diabetic foot ulcers].
Bakker K; Schaper NC
Ned Tijdschr Geneeskd; 2000 Feb; 144(9):409-12. PubMed ID: 10719543
[TBL] [Abstract][Full Text] [Related]
2. Growth factors in the treatment of diabetic foot ulcers: new technologies, any promises?
Papanas N; Maltezos E
Int J Low Extrem Wounds; 2007 Mar; 6(1):37-53. PubMed ID: 17344201
[TBL] [Abstract][Full Text] [Related]
3. The nitric oxide connection: hyperbaric oxygen therapy, becaplermin, and diabetic ulcer management.
Boykin JV
Adv Skin Wound Care; 2000; 13(4 Pt 1):169-74. PubMed ID: 11075012
[TBL] [Abstract][Full Text] [Related]
4. New treatments in ulcer healing and wound infection.
Edmonds M; Bates M; Doxford M; Gough A; Foster A
Diabetes Metab Res Rev; 2000; 16 Suppl 1():S51-4. PubMed ID: 11054889
[TBL] [Abstract][Full Text] [Related]
5. Systematic reviews of wound care management: (3) antimicrobial agents for chronic wounds; (4) diabetic foot ulceration.
O'Meara S; Cullum N; Majid M; Sheldon T
Health Technol Assess; 2000; 4(21):1-237. PubMed ID: 11074391
[TBL] [Abstract][Full Text] [Related]
6. Use of topical recombinant human platelet-derived growth factor-BB (becaplermin) in healing of chronic mixed arteriovenous lower extremity diabetic ulcers.
Miller MS
J Foot Ankle Surg; 1999; 38(3):227-31. PubMed ID: 10384364
[TBL] [Abstract][Full Text] [Related]
7. [Approval for recombinant growth factor. Since January 2000, patients with diabetic foot ulcers can be treated with the growth factor becaplermin (Regranex), manufactured with genetic technology].
Fruhstorfer B
Internist (Berl); 2000 Jan; 41(1):A38. PubMed ID: 10712088
[No Abstract] [Full Text] [Related]
8. Recombinant human platelet-derived growth factor-BB (becaplermin) for healing chronic lower extremity diabetic ulcers: an open-label clinical evaluation of efficacy.
Embil JM; Papp K; Sibbald G; Tousignant J; Smiell JM; Wong B; Lau CY
Wound Repair Regen; 2000; 8(3):162-8. PubMed ID: 10886806
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of a topical gel formulation of recombinant human platelet-derived growth factor-BB (becaplermin) in patients with chronic neuropathic diabetic ulcers. A phase III randomized placebo-controlled double-blind study.
Wieman TJ; Smiell JM; Su Y
Diabetes Care; 1998 May; 21(5):822-7. PubMed ID: 9589248
[TBL] [Abstract][Full Text] [Related]
10. The future of recombinant growth factors in wound healing.
Robson MC; Mustoe TA; Hunt TK
Am J Surg; 1998 Aug; 176(2A Suppl):80S-82S. PubMed ID: 9777977
[TBL] [Abstract][Full Text] [Related]
11. Growth factors in the treatment of diabetic foot ulcers.
Bennett SP; Griffiths GD; Schor AM; Leese GP; Schor SL
Br J Surg; 2003 Feb; 90(2):133-46. PubMed ID: 12555288
[TBL] [Abstract][Full Text] [Related]
12. Clinical evaluation of recombinant human platelet-derived growth factor for the treatment of lower extremity ulcers.
Steed DL
Plast Reconstr Surg; 2006 Jun; 117(7 Suppl):143S-149S; discussion 150S-151S. PubMed ID: 16799381
[TBL] [Abstract][Full Text] [Related]
13. Advanced biological therapies for diabetic foot ulcers.
Kirsner RS; Warriner R; Michela M; Stasik L; Freeman K
Arch Dermatol; 2010 Aug; 146(8):857-62. PubMed ID: 20713816
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of becaplermin for nonhealing neuropathic diabetic foot ulcers.
Sibbald RG; Torrance G; Hux M; Attard C; Milkovich N
Ostomy Wound Manage; 2003 Nov; 49(11):76-84. PubMed ID: 14652415
[TBL] [Abstract][Full Text] [Related]
15. Which is the better option: recombinant human PDGF-BB 0.01% gel or standard wound care, in diabetic neuropathic large plantar ulcers off-loaded by a customized contact cast?
Bhansali A; Venkatesh S; Dutta P; Dhillon MS; Das S; Agrawal A
Diabetes Res Clin Pract; 2009 Jan; 83(1):e13-6. PubMed ID: 19081156
[TBL] [Abstract][Full Text] [Related]
16. Cost effectiveness of Becaplermin in the treatment of diabetic foot ulcers in four European countries.
Ghatnekar O; Persson U; Willis M; Odegaard K
Pharmacoeconomics; 2001; 19(7):767-78. PubMed ID: 11548912
[TBL] [Abstract][Full Text] [Related]
17. Becaplermin: recombinant platelet derived growth factor, a new treatment for healing diabetic foot ulcers.
Nagai MK; Embil JM
Expert Opin Biol Ther; 2002 Feb; 2(2):211-8. PubMed ID: 11849120
[TBL] [Abstract][Full Text] [Related]
18. [News in the management of chronic neuropathic diabetic ulcer].
Meaume S
Soins; 2001 Jun; (656):12-3. PubMed ID: 12008527
[No Abstract] [Full Text] [Related]
19. Effective treatment strategies for diabetic foot wounds.
Millington JT; Norris TW
J Fam Pract; 2000 Nov; 49(11 Suppl):S40-8. PubMed ID: 11093557
[TBL] [Abstract][Full Text] [Related]
20. Use of Regranex gel for diabetic foot ulcers.
Piascik P
J Am Pharm Assoc (Wash); 1998; 38(5):628-30. PubMed ID: 9782698
[No Abstract] [Full Text] [Related]
[Next] [New Search]
